Laurus Labs Reports Strong H1 Growth and Expands
Company: Laurus Labs Limited (NSE: LAURUSLABS Laurus Labs reported consolidated revenue of ₹4,233 crore for the first half of FY27, compared with ₹3,223 crore in the corresponding period last year. The company announced H1 FY27 EBITDA of ₹1,406 crore, with an EBITDA margin of 33.2%. Its financial performance reflects growth across its pharmaceutical and contract development and manufacturing activities. Another significant development was the company's investment in Galenvs Sciences to obtain majority ownership and strengthen its capabilities in TIDES therapeutics and CDMO services. Why this matters: The CDMO business offers pharmaceutical companies an opportunity to participate in outsourced development and manufacturing. Strengthening capabilities in specialised therapeutic areas could support Laurus Labs' longer-term business positioning. What to watch next: 1. Growth in CDMO and development services. 2. Contribution from the Galenvs investment. 3. Operating margins and research-related expenditure. 4. Regulatory approvals, customer orders and execution. My view: Laurus Labs is worth tracking for its combination of pharmaceutical manufacturing and specialised CDMO capabilities. The important factor will be whether the company's investments generate sustainable revenue and profitability over time. Learning outcome: In pharmaceutical businesses, investors should evaluate the product mix, regulatory environment, research capabilities and customer relationships. Acquisitions can strengthen capabilities, but their financial benefits need to be demonstrated through execution.



















